News
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress Early clinical data show 100% ORR at 5.12 mg/kg, 100% DCR across doses, and dose-dependent tumor shrinkage; the 12 mg/kg cohort remains ongoing HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology […]
Mar 05, 2026
Read more
HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026
HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026 Monotherapy and multi-regimen combination data demonstrate a cytopenia-sparing safety profile, robust CD47 receptor occupancy, and encouraging dose-dependent antitumor activity HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical and translational data on HCB101, its […]
Feb 19, 2026
Read more
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to […]
Feb 13, 2026
Read more
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
Jan 26, 2026
Read more
HanchorBio Secures Japanese Patent for Engineered SIRPα-IgG4 Fusion Protein HCB101
HanchorBio Secures Japanese Patent for Engineered SIRPα-IgG4 Fusion Protein HCB101 Patent Approval Strengthens Global Intellectual Property Position and Supports International Licensing Strategy HanchorBio today announced that the Japan Patent Office (JPO) had granted Japanese Patent No. 7795041 covering engineered SIRPα variants and their therapeutic use, providing intellectual property protection for HCB101, the company’s differentiated […]
Jan 23, 2026
Read more
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation Mid-dose cohorts demonstrate ~80% ORR when HCB101 is layered on the standard ramucirumab and paclitaxel in second-line gastric cancer. HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today […]
Jan 09, 2026
Read more
HanchorBio Presents Preclinical Data at the SITC 2025 on HCB301, a First-in-Class Tri-Specific Immunotherapy Targeting SIRPα-CD47, PD-1/PDL1, and TGFβ
Novel fusion protein shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. [Taipei, Shanghai, and San Francisco | November 5, 2025] –HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the preclinical data on HCB301, a novel […]
Nov 06, 2025
Read more